RNA interference in biology and disease by Carol A. Sledz, and Bryan R. G. Williams Blood Volume 106(3):787-794 August 1, 2005 ©2005 by American Society.

Slides:

Advertisements

Similar presentations

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,

Advertisements

CD4 T cells: fates, functions, and faults by Jinfang Zhu, and William E. Paul Blood Volume 112(5): September 1, 2008 ©2008 by American Society.

Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease by Marilyn J. Telen Blood Volume 127(7): February 18, 2016 ©2016 by.

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.

Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo by Ilze Bot, Jian Guo, Miranda Van Eck,

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Multiple roles of the coagulation protease cascade during virus infection by Silvio Antoniak, and Nigel Mackman Blood Volume 123(17): April 24,

Volume 56, Issue 1, Pages (July 1969)

Epidemiology and Treatment of Lung Cancer in Seattle

Laboratory diagnosis and biosafety issues of biological warfare agents

Why not the liver instead of the kidney?

The influence of high-altitude living on body iron

MBL: mostly benign lymphocytes, but…

Hydroxyurea makes inflammation “just right”?

VEGF therapy: risky business for established plaques?

TCR-MHC-peptide(s): in vivo veritas

“Vitamin hypothesis”: explanation for allergy increase?

When IFN interferes with cell fate

by Henrik Frederiksen, and Kai Schmidt

Defects in DBA: more than meets the eye

by James O. Armitage, and Dan L. Longo

Gupta V, Tallman MS, Weisdorf DJ

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Zhenping Zhu Blood Volume 108(6): September 15, 2006

BTK inhibition in myeloma: targeting the seed and the soil

A cell by any other name by Narla Mohandas Blood

Transplants for the elderly in myeloma

Nonmyeloablative conditioning for relapsed follicular lymphoma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Even Individuals Considered as Long-Term Nonprogressors Show Biological Signs of Progression After 10 Years of Human Immunodeficiency Virus Infection by.

Darwinian evolution and tiding clones in multiple myeloma

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

CMV: when bad viruses turn good

RNA interference in biology and disease

An Unusual Cause of Abdominal Pain in Sickle Cell Disease

Genetic sequence analysis of inherited bleeding diseases

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Deep mining of the RBC proteome

Acute promyelocytic leukemia, microgranular variant

by Alexander Röth, Andreas Hüttmann, Russell P

by Ernest Beutler Blood Volume 98(9): November 1, 2001

An actuarial GPS for hemophilic longevity

Taking a leaf from the book of oral tolerance

Basophils take a slice of IRF8 pie

MicroRNAs: regulators of gene expression and cell differentiation

by Sabah Sallah, and Jim Y. Wan

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

Stage C or not stage C…? by Claire Dearden Blood

ROCK and Rho(ll) in bone marrow

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Latest lymphoma classification is skin deep

How I treat refractory CLL

Activity of eltrombopag in severe aplastic anemia

Laboratory diagnosis and biosafety issues of biological warfare agents

by Alex Aleshin, and Peter L. Greenberg

by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E

Molecular Therapy Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)

by Michael R. DeBaun, and Ellen Wright Clayton

Overcoming “aspirin resistance” in MPN

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Rituximab immunotherapy: it’s getting personal

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Pure red cell aplasia by Robert T. Means Blood

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Initial treatment of CLL: integrating biology and functional status

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Cold agglutinin disease

Presentation transcript:

RNA interference in biology and disease by Carol A. Sledz, and Bryan R. G. Williams Blood Volume 106(3): August 1, 2005 ©2005 by American Society of Hematology

RNA silencing pathways. Carol A. Sledz, and Bryan R. G. Williams Blood 2005;106: ©2005 by American Society of Hematology

PKR activation by dsRNA. Carol A. Sledz, and Bryan R. G. Williams Blood 2005;106: ©2005 by American Society of Hematology

Activation of IRF3 by siRNA. Carol A. Sledz, and Bryan R. G. Williams Blood 2005;106: ©2005 by American Society of Hematology